We are live on ! Find out more
TLSI icon

TriSalus Life Sciences
TLSI

72 hedge funds and large institutions have $225M invested in TriSalus Life Sciences in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 12

9% more capital invested

Capital invested by funds: $206M → $225M (+$18.5M)

0% more funds holding

Funds holding: 72 → 72 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0.01% less ownership

Funds ownership: 93.66% → 93.64% (-0.01%)

Holders
72
Holders Change
–
Holders Change %
0%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
14
Reduced
12
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FTCM
First Trust Capital Management
Illinois
+$6.38M
2
MSU
Mizuho Securities USA
New York
+$4.53M
3
AA
AQR Arbitrage
Connecticut
+$2.62M
4
Jane Street
Jane Street
New York
+$2.02M
5
BFM
Boothbay Fund Management
New York
+$1.88M

Top Sellers

Rank Fund Capital Flow
1
KC
Kryger Capital
United Kingdom
-$6.17M
2
AC
Antara Capital
New York
-$4.92M
3
MF
Magnetar Financial
Illinois
-$4.06M
4
Millennium Management
Millennium Management
New York
-$3.52M
5
Goldman Sachs
Goldman Sachs
New York
-$3.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Hudson Bay Capital Management
26
Hudson Bay Capital Management
Connecticut
$3.3M – – –
CH
27
CVI Holdings
Delaware
$2.98M – – –
SV
28
Starboard Value
New York
$2.96M – – –
BCL
29
Bracebridge Capital LLC
Massachusetts
$2.94M – – –
Barclays
30
Barclays
United Kingdom
$2.94M +$930K +94,012 +46%
Balyasny Asset Management
31
Balyasny Asset Management
Illinois
$2.85M – – –
VI
32
Vestcor Inc
New Brunswick, Canada
$2.74M – – –
MA
33
MYDA Advisors
New York
$2.68M – – –
BCM
34
Basso Capital Management
Connecticut
$2.48M -$4.47K -452 -0.2%
PC
35
Periscope Capital
Ontario, Canada
$2.22M +$831K +84,035 +60%
BFM
36
Boothbay Fund Management
New York
$2.06M +$1.88M +189,708 +1,076%
Point72 Asset Management
37
Point72 Asset Management
Connecticut
$1.99M – – –
ZCA
38
Zeke Capital Advisors
Pennsylvania
$1.99M – – –
FTCM
39
Fir Tree Capital Management
New York
$1.66M +$420K +42,450 +34%
Millennium Management
40
Millennium Management
New York
$1.66M -$3.52M -355,733 -68%
ECU
41
Eisler Capital (UK)
United Kingdom
$1.63M +$1.62M +164,122 New
SIA
42
SkyView Investment Advisors
New Jersey
$1.49M – – –
Goldman Sachs
43
Goldman Sachs
New York
$1.35M -$3.02M -305,570 -69%
KIM
44
Karpus Investment Management
New York
$1.3M – – –
AIMCA
45
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.13M +$1.12M +113,575 New
WRBC
46
W.R. Berkley Corp
Connecticut
$1.02M – – –
LCM
47
Landscape Capital Management
New Jersey
$993K +$6.93K +700 +0.7%
CM
48
Cohanzick Management
New York
$986K -$7.23K -731 -0.7%
Blackstone Inc
49
Blackstone Inc
New York
$765K – – –
SSA
50
Schonfeld Strategic Advisors
New York
$695K – – –
1
2
3 4

TLSI Hedge Fund Activity: Q3 2022 in Review

72 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q3 2022, worth a combined $225M — up 9% from $206M a quarter earlier.

Fund positioning in TLSI was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 14 added to existing stakes and 12 trimmed.

The largest buyer was First Trust Capital Management, adding an estimated $6.38M. The largest seller was Kryger Capital, cutting an estimated $6.17M.

  • 72 institutional investors held TriSalus Life Sciences (TLSI) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $225M of TriSalus Life Sciences stock for Q3 2022, up 9% quarter-over-quarter.
  • 5 funds opened new TriSalus Life Sciences positions in Q3 2022 and 5 closed out, a net change of 0 holders.
  • The largest TriSalus Life Sciences buyer in Q3 2022 was First Trust Capital Management, an estimated $6.38M added.
  • The largest TriSalus Life Sciences seller in Q3 2022 was Kryger Capital, an estimated $6.17M sold.

Based on aggregated 13F filings for Q3 2022.